Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis.
Burles A Johnson IiiBenjamin A TeplyCatherine KagemannBridget McGuireKara LombardoYuezhou JingWilliam LangboJonathan I EpsteinGeorge J NettoAlex S BarasAndres MatosoDavid J McConkeyAmol GuptaNita AhujaAshley E RossPhillip M PierorazioEva ComperatJean Hoffman-CensitsNirmish SinglaSunil H PatelMax KatesWoonyoung ChoiTrinity J BivalacquaNoah M HahnPublished in: Bladder cancer (Amsterdam, Netherlands) (2024)
SBC is a chemosensitive subtype, with ypCR rate similar to urothelial bladder cancer following CGD neoadjuvant therapy. Whole transcriptome tissue analyses demonstrate increased expression of immune checkpoint and T-cell genes with therapeutic implications.
Keyphrases
- locally advanced
- rectal cancer
- genome wide
- squamous cell carcinoma
- radiation therapy
- poor prognosis
- lymph node
- rna seq
- gene expression
- high grade
- urinary tract
- binding protein
- stem cells
- muscle invasive bladder cancer
- bioinformatics analysis
- long non coding rna
- bone marrow
- genome wide identification
- mesenchymal stem cells
- transcription factor